Macrogenics' Partner Gilead Sciences Nominated The First Of Two Research Programs, Leveraging Macrogenics' DART And TRIDENT Platforms For Generating Bispecific Antibodies, Triggering A Milestone Payment Of $15M
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences has nominated the first of two research programs, leveraging Macrogenics' DART and TRIDENT platforms for generating bispecific antibodies. This triggers a milestone payment of $15M to Macrogenics.
September 05, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead Sciences' nomination of the first research program could potentially lead to advancements in their product pipeline, which may positively impact their stock in the short term.
The nomination of the research program indicates Gilead's commitment to leveraging Macrogenics' platforms, which could potentially lead to advancements in their product pipeline. This could be seen as a positive development by investors, potentially leading to a short-term increase in Gilead's stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Macrogenics receives a $15M milestone payment from Gilead Sciences, which could positively impact their revenue and potentially their stock price in the short term.
The $15M milestone payment from Gilead Sciences directly contributes to Macrogenics' revenue. This could be seen as a positive development by investors, potentially leading to a short-term increase in Macrogenics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100